Epanova® for Lowering Very High Triglycerides
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.
Also called NCT01242527
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 399 participants
- Sponsor
- Registry
-
NCT01242527
-
- Other papers using this trial's data
- Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Denmark, Hungary, India, Netherlands, Russia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01242527. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-09-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Epanova® for Lowering Very High Triglycerides
- Acronym
- EVOLVE
- Condition
- Severe Hypertriglyceridemia
- Intervention (Drug)
- placebo
- Intervention (Drug)
- omefas
- Intervention (Drug)
- omefas
- Intervention (Drug)
- omefas
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01242527- Content hash
62bd41bdc88171e2f31c73131191523f60df03c6b0f77ccda91080ae9cc7c975